Division of Gynecologic Surgery, the Department of Anesthesiology, Hospital Pharmacy Services, the Department of Nursing, the Division of Biomedical Statistics and Informatics, and the Department of Health Sciences, Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota.
Obstet Gynecol. 2013 Aug;122(2 Pt 1):319-328. doi: 10.1097/AOG.0b013e31829aa780.
To investigate the effects of enhanced recovery (a multimodal perioperative care enhancement protocol) in patients undergoing gynecologic surgery.
Consecutive patients managed under an enhanced recovery pathway and undergoing cytoreduction, surgical staging, or pelvic organ prolapse surgery between June 20, 2011, and December 20, 2011, were compared with consecutive historical controls (March to December 2010) matched by procedure. Wilcoxon rank-sum, χ, and Fisher's exact tests were used for comparisons. Direct medical costs incurred in the first 30 days were obtained from the Olmsted County Healthcare Expenditure and Utilization Database and standardized to 2011 Medicare dollars.
A total of 241 enhanced recovery women in the case group (81 cytoreduction, 84 staging, and 76 vaginal surgery) were compared with women in the control groups. In the cytoreductive group, patient-controlled anesthesia use decreased from 98.7% to 33.3% and overall opioid use decreased by 80% in the first 48 hours with no change in pain scores. Enhanced recovery resulted in a 4-day reduction in hospital stay with stable readmission rates (25.9% of women in the case group compared with 17.9% of women in the control group) and 30-day cost savings of more than $7,600 per patient (18.8% reduction). No differences were observed in rate (63% compared with 71.8%) or severity of postoperative complications (grade 3 or more: 21% compared with 20.5%). Similar, albeit less dramatic, improvements were observed in the other two cohorts. Ninety-five percent of patients rated satisfaction with perioperative care as excellent or very good.
Implementation of enhanced recovery was associated with acceptable pain management with reduced opioids, reduced length of stay with stable readmission and morbidity rates, good patient satisfaction, and substantial cost reductions.
II.
研究强化康复(一种多模式围手术期护理增强方案)对妇科手术患者的影响。
将 2011 年 6 月 20 日至 12 月 20 日期间接受减瘤术、手术分期或盆腔器官脱垂手术且采用强化康复途径管理的连续患者与通过手术匹配的连续历史对照(2010 年 3 月至 12 月)进行比较。Wilcoxon 秩和检验、卡方检验和 Fisher 确切概率检验用于比较。将前 30 天内发生的直接医疗费用从奥姆斯特德县医疗保健支出和利用数据库中获取,并标准化为 2011 年医疗保险美元。
在病例组中共有 241 名强化康复患者(81 例减瘤术,84 例分期术,76 例阴道手术),与对照组的患者进行比较。在减瘤组中,患者自控麻醉的使用率从 98.7%降至 33.3%,术后前 48 小时内阿片类药物总用量减少了 80%,而疼痛评分无变化。强化康复使住院时间缩短了 4 天,再入院率稳定(病例组中 25.9%的女性与对照组中 17.9%的女性),每位患者的 30 天节省成本超过 7600 美元(18.8%的降幅)。两组患者术后并发症的发生率(63%与 71.8%)或严重程度(3 级或更高级别:21%与 20.5%)均无差异。在其他两组中也观察到了类似的但不那么显著的改善。95%的患者对围手术期护理的满意度评价为优秀或非常好。
实施强化康复与可接受的疼痛管理相关,阿片类药物用量减少,住院时间缩短,再入院率和发病率稳定,患者满意度高,成本大幅降低。
II 级。